Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 34791298.
- Also identified by DOI 10.1093/infdis/jiab570 and PMC identifier 8767864.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Breakthrough coronavirus disease 2019 (COVID-19) may occur in fully vaccinated persons. We assessed the clinical outcomes of breakthrough COVID-19 in fully vaccinated individuals. In this cohort of 1395 persons (mean age, 54.3 years; 60% female; median body mass index, 30.7) who developed breakthrough COVID- 19, there were 107 (7.7%) who required hospitalization by day 28. Hospitalization was significantly associated with the number of medical comorbidities. Antispike monoclonal antibody treatment was significantly associated with a lower risk of hospitalization (odds ratio, 0.227; 95% confidence interval, 0.128-0.403; P < .001). The number needed to treat (NNT) to prevent 1 hospitalization was 225 among the lowest risk patient group compared with NNT of 4 among those with highest numbers of medical comorbidity. Monoclonal antibody treatment is associated with reduced hospitalization in vaccinated high-risk persons with mild to moderate COVID-19.
Medical subject headings
- Antibodies, Monoclonal
- COVID-19
- Vaccination